Clinical packaging and labeling is the work of taking an investigational medicinal product and turning it into something a trial site can dispense to a patient on day one. Wallets, kits, multi-language patient labels, randomization codes, IRT-compatible barcodes. Done well it disappears into the trial protocol. Done badly it becomes the reason recruitment slows, sites complain, and the read-out slides by months.
What clinical packaging actually covers
Two layers of work, both regulated, both error-sensitive:
Packaging. The blister, the wallet, the kit. Whatever holds the IMP and the placebo (if blinded). For Phase I you might ship 500 units total. For Phase III maybe 50,000. Format flexibility matters more than throughput at trial volumes.
Labeling. Patient labels, kit labels, carton labels, booklet labels for multi-language trials. Each label has to satisfy local regulatory requirements (EU CTR, FDA 21 CFR 312, ICH GCP) and integrate with the IRT/RTSM system at every site.
Where labeling breaks trials
Three patterns we see consistently:
Translation errors caught at site activation. The booklet label was translated into nine languages, two of them have errors that the site coordinator catches on day one. Recruitment delays a week while you reprint and reship.
IRT integration mismatch. The kit code on the wallet doesn't scan correctly with the IRT system at three out of seventeen sites. Sites can't dispense, patients sit in the waiting room.
Regulatory compliance gaps. The label satisfies EU CTR but not FDA 21 CFR. The trial is multi-region and you didn't catch the mismatch until the FDA inspector asked.
All preventable with rigorous label management and integration testing before site shipment.
Why low volume changes everything
A lot of contract packers struggle with trial supply because their economics depend on high throughput. Setup time and validation costs amortize over millions of packs. Drop the volume to 5,000 packs across three cohorts and the math doesn't work for them.
A serious trial supply partner runs low-volume work as part of their standard model, not as a favor. We do, because most of what we ship for clinical trials is low-volume specialty work and the lines are validated for that scale from the start.
Cold seal wallets for clinical trials
Most of our trial supply work runs in cold seal blister wallets. The format suits trials for three reasons: low MOQ tolerance (we run 500-unit batches), fast format change between cohorts, and wallet calendar layouts for adherence-sensitive protocols.
For trials with pediatric exposure or schedule-controlled APIs, we add child-resistance via the Locked4Kids platform. Same wallet, same line, different feature set.
Clinical-to-commercial handoff
If the trial reads out positive, the same packaging line should scale to commercial volumes without re-validation. That's a property of the partner, not a guarantee.
We run trial supply and commercial production on the same lines, validated for both. The wallet that ships 500 trial units in Phase II ships 5,000,000 commercial units after launch, with no protocol re-validation.
If you're scoping clinical packaging
The conversation starts with the protocol: regimen, cohort structure, languages, cold chain, IRT system, regulatory regions. From there we work backward to the wallet and the labels. Send us the protocol and we'll come back with a packaging concept and a timeline. Or read more about our clinical trial packaging service.
Request a free sample now!
